AI Aced the Boards. It Failed the Clinic. The Kenya Trial Reveals a Gap the Industry Can’t Ignore.
A cluster-RCT across 16 Kenya primary care clinics found ChatGPT-4o-assisted decision support improved documentation but missed on patient outcomes...
Silo Pharma Reports Stability Data for SPC-15 PTSD Treatment
Silo Pharma's SPC-15 PTSD treatment passes nine months of stability testing, clearing a key CMC milestone toward IND submission...
Seres to Present SER-155 Data for Checkpoint Inhibitor Enterocolitis
Seres presents SER-155 data for checkpoint inhibitor enterocolitis, targeting a steroid-sparing approach to oncology-related toxicity management.
GCP Breakdown at King’s College Hospital Just Clouded the Most Promising Parkinson’s Trial in Years
An MHRA inspection at King's College Hospital flagged department-wide GCP failures in the exenatide Phase 3 Parkinson's trial, triggering...
ProQR’s AX-0810 Shows Target Engagement in Phase 1 Study
ProQR's AX-0810 Phase 1 study demonstrates target engagement through an 8-fold increase in serum bile acids, validating the Axiomer...
Innovative Molecules Starts Phase 2a Trial of Adibelivir for Genital Herpes
Innovative Molecules launches Phase 2a Trial of Adibelivir for genital herpes, testing a helicase-primase inhibitor against acyclovir-resistant strains.
FDA Backs Entera Bio’s Phase 3 Plan for Oral EB613 Osteoporosis Drug
FDA backs Entera Bio's Phase 3 plan for oral EB613 osteoporosis drug, targeting injection-free anabolic therapy for postmenopausal women.
Phathom Completes Enrollment in Phase 2 Vonoprazan EoE Trial Ahead of Schedule
Phathom completes Phase 2 Vonoprazan EoE Trial ahead of schedule with 95 patients enrolled. Topline data expected by Q4...
When Your CRO’s AI Platform Upgrades, Who Pays for the Change Management?
Icon's Microsoft-Copilot partnership scales its Orbis AI platform enterprise-wide. For sites and sponsors mid-trial, the operational cost question starts...
GENFIT’s GNS561 Shows No Dose-Limiting Toxicities in Cholangiocarcinoma Phase 1b
GENFIT's GNS561 shows no dose-limiting toxicities in Phase 1b cholangiocarcinoma trial combining autophagy inhibition with MEK inhibition in KRAS-mutated...